Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis

Table 3

Therapy of 124 TNBC patients assessed for BRCA1/2 mutations.

Type of therapy	Patients tested for BRCA mutations				value (BRCA-positive vs BRCA-negative)
	BRCA noncarriers	Rate (%)	BRCA carriers	Rate (%)
Number of patients	94	100	30	100
Surgery
Yes	90	96	29	97	0.7004
No	4	4	1	3
Type of surgery
Mastectomy	60/90	66.5	17/29	58.5	0.2438
Breast-conserving surgery	30/90	33.5	12/29	41.5
Radiotherapy
Yes	55	58.5	17	56.5	0.7751
No	39	41.5	13	43.5
Radiotherapy
After mastectomy	27/55	49	5/17	29.5	0.0044
After breast-conserving surgery	28/55	51	12/17	70.5
Neoadjuvant chemotherapy
Yes	20	21.5	4	13.5	0.0940
No	74	78.5	26	86.5
Regimens in neoadjuvant chemotherapy
AT⟶CMF	5/20	25	1/4	25	<0.0001
Anthracycline + taxane	9/20	45	2/4	50
Anthracycline	5/20	5	1/4	25
Others	1/20	25	0	0
Adjuvant chemotherapy
Yes	64	68	23	76.5	0.1541
No	30	32	7	23.5
Regimens in adjuvant chemotherapy
Anthracycline (AC)	41/64	64	12/23	52	0.0574
FEC/FAC	11/64	17.5	4/23	17.5
Anthracycline + taxane	8/64	12.5	5/23	21.5
CMF	2/64	3	0	0
Taxane	2/64	3	2/23	9